Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. - Strik, A. S.; Brink, G. R.; Ponsioen, C.; Mathot, R.; Löwenberg, M.; D'Haens, G. R. (Alimentary Pharmacology & Therapeutics, 2017)